拟人参皂苷F11在大鼠体内的药物代谢研究

目的探讨拟人参皂苷F11在大鼠体内的药物代谢产物及其过程.方法ip拟人参皂苷F₁₁后,应用TLC分析排泄物中的代谢产物,并利用制备薄层分离制备代谢产物,通过波谱解析(MS,¹HNMR,¹³CNMR,¹H-¹HCOSY)确定其结构.结果从粪便中分离鉴定了3种代谢产物,分别为拟人参皂苷R_T5,ocotillol和1个新的代谢产物F-3-1,并确定其结构为6-O-α-L-吡喃鼠李糖基(1-2)-β-D-吡喃葡糖基-(20S,23S,24R)-达玛-20(24)-环氧-3β,6α,12β,23,25-五醇(6-O-α-L-rhamnopyranosyl-(1-2)-β-D-glucopyranosyl-(20S,23S,24R)-dammar-20(24)-epoxy-3-β,6α,12β,23,25-pentanol).但在尿液和胆汁中并未发现任何代谢产物.结论拟人参皂苷F₁₁不被肝脏代谢,但胆汁排泄物可在肠道被代谢为水解和氧化产物.

STUDY ON THE METABOLISM OF PSUEDO-GINSENOSIDE F11 IN RATS

AIM: To study the metabolic pathways of psuedo-ginsenoside F11 in rats. METHODS: By use of the prep-TLC, the metabolites were isolated. RESULTS: From the feces, three metabolites, psuedo-ginsenoside-RT5, ocotillol, and a new compound, F-3-1 (44) were isolated and identified by means of NMR evidence. But, such metabolites were found from neither the bile nor the urine of the rat. F-3-1 was identified as 6-O-alpha-L-rhamnopyranosyl-(1-2)-beta-D-glucopyranosyl-(20S,23S,24R)- dammar-20(24)-epoxy-3 beta, 6 alpha, 12 beta, 23,25-pentanol. CONCLUSION: Psuedo-ginsenoside-F11 can not be metabolized in the rat liver, but can be metabolized in the large intestine of the rat.